- Home
- FGI vs MYNZ Comparison
FGI vs MYNZ Comparison
Compare FGI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- MYNZ
- Stock Information
- Founded
- FGI 1987
- MYNZ 2021
- Country
- FGI United States
- MYNZ Germany
- Employees
- FGI N/A
- MYNZ N/A
- Industry
- FGI Industrial Specialties
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- FGI Industrials
- MYNZ Health Care
- Exchange
- FGI Nasdaq
- MYNZ Nasdaq
- Market Cap
- FGI 6.6M
- MYNZ 5.5M
- IPO Year
- FGI 2022
- MYNZ 2021
- Fundamental
- Price
- FGI $0.60
- MYNZ $1.37
- Analyst Decision
- FGI
- MYNZ Buy
- Analyst Count
- FGI 0
- MYNZ 2
- Target Price
- FGI N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- FGI 230.6K
- MYNZ 118.7K
- Earning Date
- FGI 08-06-2025
- MYNZ 07-07-2025
- Dividend Yield
- FGI N/A
- MYNZ N/A
- EPS Growth
- FGI N/A
- MYNZ N/A
- EPS
- FGI N/A
- MYNZ N/A
- Revenue
- FGI $134,277,102.00
- MYNZ $893,991.00
- Revenue This Year
- FGI $7.72
- MYNZ $26.06
- Revenue Next Year
- FGI $6.94
- MYNZ $4.97
- P/E Ratio
- FGI N/A
- MYNZ N/A
- Revenue Growth
- FGI 11.13
- MYNZ N/A
- 52 Week Low
- FGI $0.46
- MYNZ $1.34
- 52 Week High
- FGI $1.36
- MYNZ $22.40
- Technical
- Relative Strength Index (RSI)
- FGI 49.90
- MYNZ 23.25
- Support Level
- FGI $0.56
- MYNZ $1.34
- Resistance Level
- FGI $0.85
- MYNZ $1.48
- Average True Range (ATR)
- FGI 0.08
- MYNZ 0.13
- MACD
- FGI -0.01
- MYNZ -0.01
- Stochastic Oscillator
- FGI 30.00
- MYNZ 3.72
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.